Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

A federal judge just invoked Star Trek in a $5 billion patent ruling against Moderna. Here is why the mRNA giant is heading ...

Moderna faces a $5b patent infringement lawsuit over its COVID-19 vaccine, now moving to trial after a key court ruling. The ...

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

Wall Street expects a year-over-year decline in earnings on lower revenues when Moderna (MRNA) reports results for the ...

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David ...

The vaccine maker is expanding beyond its COVID-focused offerings.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study.

What Is Driving the Updated Fair Value for Moderna? Analyst models on Moderna have been refreshed, with the fair value ...

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.